P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)



Status:Recruiting
Conditions:Blood Cancer, Hematology, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:3/27/2019
Start Date:September 20, 2017
End Date:June 30, 2022
Contact:Michelle Resler
Email:mresler@poseida.com
Phone:1-858-779-3100

Use our guide to learn which trials are right for you!

Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects With Relapsed and/or Refractory Multiple Myeloma (MM)

This is a Phase 1, open-label, multi-center study of P-BCMA-101 autologous T stem cell memory
(Tscm) CAR-T cells in patients with relapsed and/or refractory MM. Rimiducid may be
administered as indicated.

The study will follow a 3 + 3 design of dose-escalating cohorts. After a patient enrolls,
leukapheresis will be performed to obtain peripheral blood mononuclear cells which will be
sent to a manufacturing site to produce P-BCMA-101 CAR-T cells. The cells will then be
returned to the investigational site and, after a standard chemotherapy based conditioning
regimen, will be administered to the patient. Treated patients will undergo serial
measurements of safety, tolerability and response. Rimiducid may be administered as
indicated.

Inclusion Criteria:

- Males or females, ≥18 years of age

- Must have a confirmed diagnosis of active MM

- Must have measurable MM

- Must have relapsed and/or refractory MM, having received treatment with proteasome
inhibitor and IMiD

- Must have adequate hepatic, renal, cardiac and hematopoietic function

Exclusion Criteria:

- Is pregnant or lactating

- Has inadequate venous access and/or contraindications to leukapheresis

- Has active hemolytic anemia, plasma cell leukemia, Waldenstrom's macroglobulinemia,
POEMS syndrome, amyloidosis, significant autoimmune, CNS or other malignant disease

- Has an active systemic infection

- Has any psychiatric or medical disorder that would preclude safe participation in
and/or adherence to the protocol

- Has receiving immunosuppressive or other contraindicated therapies within the excluded
time frame from entry

- Has CNS metastases or symptomatic CNS involvement

- Has a history of having undergone allogeneic stem cell transplantation, or any other
allogeneic or xenogeneic transplant
We found this trial at
6
sites
3400 N Charles St
Baltimore, Maryland 21205
410-516-8000
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
343
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
1721 East 19th Ave., Suite #200 & #300
Denver, Colorado 80218
720-754-4800
Colorado Blood Cancer Institute When patients come to the Colorado Blood Cancer Institute, the entire...
1161
mi
from 43215
Denver, CO
Click here to add this to my saved trials
Houston, Texas 77030
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
333
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
San Diego, California 92093
1926
mi
from 43215
San Diego, CA
Click here to add this to my saved trials